V.A.C.? DRESSING VACDSP

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a health professional report with the FDA on 2020-03-25 for V.A.C.? DRESSING VACDSP manufactured by Kinetic Concepts, Inc..

Event Text Entries

[188563225] Other (code unspecified): device identifier was not provided and product was not returned. Based on information provided, it cannot be determined that the bleeding was related to the v. A. C.? Dressing. It is unknown when the foreign body alleged to be v. A. C.? Dressing was placed in the wound. The foreign material was not returned to kci for identification; therefore, kci is unable to confirm its identity. Device labeling, available in print and online, states:warningswith or without using v. A. C.? Therapy, certain patients are at high risk of bleeding complications. The following types of patients are at increased risk of bleeding, which, if uncontrolled, could be potentially fatal. Patients who have weakened or friable blood vessels or organs in or around the wound as a result of, but not limited to:suturing of the blood vessel (native anastomosis or grafts)/organ,infection,trauma,radiation,patients without adequate wound hemostasis,patients who have been administered anticoagulants or platelet aggregation inhibitors,patients who do not have adequate tissue coverage over vascular structures. If v. A. C.? Therapy is prescribed for patients who have an increased risk of bleeding complications, they should be treated and monitored in a care setting deemed appropriate by the treating physician. If active bleeding develops suddenly or in large amounts during v. A. C.? Therapy, or if frank (bright red) blood is seen in the tubing or in the canister, immediately stop v. A. C.? Therapy, leave dressing in place, take measures to stop the bleeding and seek immediate medical assistance. The v. A. C.? Therapy units and dressings should not be used to prevent, minimize or stop vascular bleeding.? Protect vessels and organs: all exposed or superficial vessels and organs in or around the wound must be completely covered and protected prior to the administration of v. A. C.? Therapy. Keep v. A. C. Therapy on: never leave a v. A. C.? Dressing in place without active v. A. C.? Therapy for more than two hours. If therapy is off for more than two hours, remove the old dressing and irrigate the wound. Either apply a new v. A. C.? Dressing from an unopened sterile package and restart v. A. C.? Therapy, or apply an alternative dressing as the direction of the treating physician. Dressing changeswounds being treated with the v. A. C.? Therapy system should be monitored on a regular basis. In a monitored, non-infected wound, v. A. C.? Dressings should be changed every 48-72 hours, but no less than 3 times a week, with frequency adjusted by the clinician as appropriate. Infected wounds must be monitored often and very closely. For these wounds, dressings may need to be changed more often than 48-72 hours; the dressing changing intervals should be based on a continuing evaluation of the wound condition and the patient's clinical presentation, rather than a fixed schedule. Foam removal:v. A. C.? Foam dressings are not bioabsorbable. Always count the total number of pieces of foam removed from the wound and ensure the same number of foam pieces are removed as were placed. Foam left in the wound for greater that the recommended time period may foster ingrowth of tissue into the foam, create difficulty in removing the foam from the wound or lead to infection or other adverse events. If dressing adheres to wound consider introducing sterile water or normal saline into the dressing, waiting 15 - 30 minutes, then gently removing the dressing from the wound. Regardless of treatment modality, disruption of the new granulation tissue during any dressing change may result in bleeding at the wound site. Minor bleeding may be observed and considered expected. However, patients with increased risk of bleeding, as described on page 8, have a potential for more serious bleeding from the wound site. As a precautionary step, consider using v. A. C.? Whitefoam? Dressings or nonadherent material underneath the v. A. C.? Granufoam? Dressings to help minimize the potential for bleeding at dressing removal in these patients.
Patient Sequence No: 1, Text Type: N, H10


[188563226] On 24-feb-2020, the following information was reported to kci by the nurse: a foreign material alleged to be v. A. C.? Dressing was adhered to the patient's wound. On 28-feb-2020, the following information was reported to kci by the nurse: the dressing was manually removed which allegedly caused the wound to bleed. The patient underwent cauterization to resolve the bleeding. The v. A. C.? Dressing type and lot number were not provided and the product was not returned; therefore, a device history review and a device evaluation could not be performed.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3009897021-2020-00120
MDR Report Key9881245
Report SourceHEALTH PROFESSIONAL
Date Received2020-03-25
Date of Report2020-03-25
Date of Event2020-02-24
Date Mfgr Received2020-02-24
Date Added to Maude2020-03-25
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMR STEVEN JACKSON
Manufacturer Street6203 FARINON DRIVE
Manufacturer CitySAN ANTONIO, TX
Manufacturer CountryUS
Manufacturer Phone2556438
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameV.A.C.? DRESSING
Generic NameOMP
Product CodeOMP
Date Received2020-03-25
Model NumberVACDSP
Lot NumberASKU
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrN
Device Sequence No1
Device Event Key0
ManufacturerKINETIC CONCEPTS, INC.
Manufacturer AddressSAN ANTONIO, TX US


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2020-03-25

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.